Agios scraps blood disorder drug program after study miss
Agios scraps blood disorder drug program after study miss May 29 (Reuters) - Agios Pharmaceuticals AGIO.O said on Friday it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show enough benefit.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed)
Recent news on Agios Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Agios Q2 revenue jumps on US commercial launch of AQVESME
Brief: Agios Pharmaceuticals Q2 Product Revenue USD 44.745 Million Vs. IBES Estimate USD 25.5 Million